1. 71PPhase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data. (17th December 2018) Authors: Owonikoko, T K; Papadopoulos, K P; Johnson, M L; Gil Martín, M; Moreno, V; Salama, A K; Calvo, E; Yee, N S; Safran, H; Aljumaily, R; Mahadevan, D; Niu, J; Kal Mohan, K; Li, J; Stankevich, E; Mathias, M; Lowy, I; Fury, M G; Babiker, H M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 10 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1243TiPPhase I study of BI 754111 (anti-LAG-3) plus BI 754091(anti-PD-1) in patients (pts) with advanced solid cancers, followed by expansion in pts with microsatellite stable metastatic colorectal cancer (mCRC), anti-PD-(L)1-pretreated non-small cell lung cancer (NSCLC) and other solid tumors. (23rd October 2018) Authors: Johnson, M L; Patel, M R; Ulahannan, S V; Hansen, A; George, B; Chu, Q S-C; Elgadi, M; Ge, M; Duffy, C; Graeser, R; Khedkar, S; Jones, S F; Burris, H Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 72PCemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2). (17th December 2018) Authors: Moreno, V; Gil-Martin, M; Johnson, M L; Aljumaily, R; Lopez Criado, P; Northfelt, D W; Crittenden, M; Jabbour, S; Rosen, L; Garrido, P; Hervás Morón, A; Rietschel, P; Mohan, K K; Li, J; Stankevich, E; Feng, M; Lowy, I; Fury, M G Journal: Annals of oncology Issue: Volume 29(2018)Supplement 10 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 93O First results of phase I/II studies evaluating viral vector-based heterologous prime/boost immunotherapy against predicted HLA class I neoantigens demonstrate CD8 T cell responses in patients with advanced cancers. (15th December 2019) Authors: Johnson, M L; Spira, A; Carbone, D P; Drake, C; Henick, B; Ingham, M; Caldwell, K; Chan, S; Hart, M; Malloy, A; Maloney, E; Palmer, C; Yang, A; Zhong, M; Basciano, P; Bournazou, E; Ferguson, A R; Catenacci, D Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 1275PSafety and clinical activity of subcutaneously (SC) administered anti-PD-1 antibody PF-06801591 in phase I dose-expansion cohorts of locally advanced or metastatic non-small cell lung cancer (NSCLC) and urothelial carcinoma (UC). (1st October 2019) Authors: Cho, B C; Penkov, K; Bondarenko, I; Korozan, M; Kurochkin, A; Pikiel, J; Kulyaba, Y; Ahn, H K; Odintsova, S; Davda, J; Forgie, A; Wang, X; Li, R; Jacobs, I A; Kazazi, F; Chou, J; Johnson, M L Journal: Annals of oncology Issue: Volume 30(2019)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Skin lesions in ulcerative colitis. Issue 4 (April 1969) Authors: Johnson, M L; Wilson, H T Journal: Gut Issue: Volume 10:Issue 4(1969) Page Start: 255 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗